Ayala Pharmaceuticals, Inc. (ADXS)

OTCMKTS · Delayed Price · Currency is USD

0.105

+0.075 (250.33%)

Feb 21, 2025, 3:00 PM EST

Ayala Pharmaceuticals Employees

As of December 31, 2023, Ayala Pharmaceuticals had 21 total employees, including 20 full-time and 1 part-time employees.

Employees

21

Change

n/a

Growth

n/a

Revenue / Employee

$619

Profits / Employee

-$2,289,143

Market Cap

5.18M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	21	-	-

Related Stocks

Company Name	Employees
Endo Inc.	2,931
Elite Pharmaceuticals	64
Glass House Brands	413
Northwest Biotherapeutics	25
CytoDyn	9
Silence Therapeutics	109
SANUWAVE Health	31

Employee Rankings

Ayala Pharmaceuticals News

24 days ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire
24 days ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline - Business Wire
10 months ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
11 months ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
1 year ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
1 year ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
1 year ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
1 year ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire